Citation Impact
Citing Papers
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
2012
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
2011
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
2015
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab
2007
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
2010
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Moving targets: Emerging roles for MMPs in cancer progression and metastasis
2015
Immunotherapy of cancer in 2012
2012
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Cancer burden in the year 2000. The global picture
2001 Standout
A view on drug resistance in cancer
2019 StandoutNature
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
2008
Global Cancer Statistics, 2002
2005 Standout
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
2010
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
2017
The biology and management of non-small cell lung cancer
2018 StandoutNature
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2011
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
2004 Standout
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Lung Cancer
2008 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial
2008
Improving de novo protein binder design with deep learning
2023 StandoutNobel
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Development trends for human monoclonal antibody therapeutics
2010
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
2006
Pancreatic Adenocarcinoma
2014 Standout
Colorectal cancer
2019 Standout
Dose‐intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first‐line treatment of advanced or metastatic adult soft tissue sarcoma
2008
Cetuximab for the Treatment of Colorectal Cancer
2007
Global cancer statistics
2011 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Chemotherapy Maintenance
2016
In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes
2014
Targeting apoptosis in cancer therapy
2020 Standout
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group
2008
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
2015
EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy
2013
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Cancer immunotherapy comes of age
2011 StandoutNature
Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
2014
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial
2011
Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH
2014
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
2008
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Predictive value of MMP‐7 expression for response to chemotherapy and survival in patients with non‐small cell lung cancer
2008
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
2012
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
2014
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
2007
A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003
2007
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Biomarker-driven and molecular targeted therapies for colorectal cancers
2017
Cetuximab in the treatment of colorectal cancer.
2004
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
2008
Multifaceted Immunomodulatory Nanoliposomes: Reshaping Tumors into Vaccines for Enhanced Cancer Immunotherapy
2017
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
2014
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
2013
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
2007
Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies
2015
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
2010
What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long‐term outcomes over the past decades? A systematic review and meta‐analysis based on 41,121 patients
2017
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Panitumumab, a Monoclonal Anti–Epidermal Growth Factor Receptor Antibody in Colorectal Cancer: Another One or the One?
2007
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Molecular Pathobiology of Gastrointestinal Stromal Sarcomas
2008
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
2017
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
2009
High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History
2007
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
2008
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Immune Therapy for Cancer
2008
Works of Joan Maurel being referenced
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
2011
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
2011
Treatment effect of panitumumab in subsets by epidermal growth factor receptor (EGFR) status from a phase 3 randomized controlled trial
2006
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
2012
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
2007
Recent time trends in cancer of the oesophagus and gastric cardia in the region of Calvados in France, 1978–1995
1999
Salvage surgical resection after high‐dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): A potential positive selection bias—A study of the Spanish Group for Research on Sarcomas (GEIS)
2004
The Role of MMP7 and Its Cross-Talk with the FAS/FASL System during the Acquisition of Chemoresistance to Oxaliplatin
2009
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer
2006
Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients
2016
A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma
2005
Serum Matrilysin Levels Predict Outcome in Curatively Resected Colorectal Cancer Patients
2009
Sequential dose‐dense doxorubicin and ifosfamide for advanced soft tissue sarcomas
2004
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial
2015
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
2008
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab
2010
Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients
2007
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
2013
3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial
2007
A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC)
2009
Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas
2009
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
2007
Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial
2007
Role of metalloproteinase-7 in oxaliplatin acquired resistance in colorectal cancer cell lines
2006
Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS)
2005
Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)
2006
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
2007
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
2008